NewGeneris is applying advanced biomarker technology in the context of molecular epidemiology studies based on a number of European mother-child birth cohorts, to test the hypothesis that maternal exposure to dietary compounds with carcinogenic and immunotoxic properties results in in utero exposure and molecular events in the unborn child which ultimately lead to increased risk of cancer and immune disorders in later childhood. It is also using novel approaches to discover new, relevant biomarkers, to evaluate the importance of paternal exposure at the time of conception, and to assess the influence on fetal exposure of placental transport of toxic chemicals to which the mother is exposed.